bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 14,754 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Follow-Up Questions
BMXMF hissesinin fiyat performansı nasıl?
BMXMF 'in mevcut fiyatı $134.24 'dir, son işlem günde 0% decreased etti.
Biomerieux SA için ana iş temaları veya sektörler nelerdir?
Biomerieux SA Health Care endüstrisine ait ve sektör Health Care 'dir
Biomerieux SA 'in piyasa değerlemesi nedir?
Biomerieux SA 'in mevcut piyasa değerlemesi $15.8B 'dir
Biomerieux SA al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 16 analist Biomerieux SA için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 9 al, 6 tut, 1 sat ve 2 güçlü sat içermektedir
